• Jing Lin, Rong-Zu Tu, and Xun-Yu Hong.
• Department of Health Management Center, Ningbo Women and Children's Hospital, Zhejiang, China,Department of Education, Ningbo Women and Children's Hospital, Zhejiang, China,Department of Internal Medicine, Ningbo Women and Children's Hospital, Zhejiang, China.
• Medicine (Baltimore). 2022 Mar 18; 101 (11).

BackgroundThe increased prevalence of gestational diabetes mellitus (GDM) has caused a huge societal economic and healthy burden at both the population and individual levels. We aimed to assess the comparative efficiency and safety of the use of glyburide, metformin, and insulin in GDM from a protocol for systematic review and meta-analysis.MethodsTwo individual researchers conducted the platform searches on the PubMed, Cochrane Library, and Embase databases from inception to February 2022. Literature retrieving was carried out through a combined searching of subject terms ("MeSH" on PubMed and "Emtree" on "Embase") and free terms on the platforms of PubMed and Embase, and through keywords searching on platform of Cochrane Library. Systematic review and meta-analysis of the data will be performed in STATA13.0 software according to the Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Two authors independently performed the literature searching, data extraction, and quality evaluation. Risk of bias was assessed using the Cochrane Risk of Bias Tool for randomized controlled trials.ResultsThe results will be submitted to a peer-reviewed journal.ConclusionThis meta-analysis will provide a comprehensive analysis and synthesis that can be used as an evidence map to inform practitioners and policy makers about the effectiveness of glyburide, metformin, and insulin for patients with GDM.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

33 keywords...

hide…